^
    The Tempus xT next generation sequencing assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available. The fourth version of the xT assay (v4) covers 648 genes spanning ~3.6 Mb of genomic space. From DNA sequencing, somatic and incidentally detected germline single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs) and translocations in 22 genes are detected, along with two promoter regions (PMS2 and TERT) and 239 sites to determine microsatellite instability status. The assay requires specimens with a tumor content of 20% post macrodissection (minimum 30% for MSI status). For solid tumors, an FFPE tumor sample is sequenced along with a matched normal blood or saliva sample. The xT assay is used across a diverse set of clinical settings including leading academic centers, NCI designated cancer centers, hospital networks, and community hospitals.
    Cancer:
    Colorectal Cancer, Solid Tumor
    Gene:
    ABCB1 (ATP Binding Cassette Subfamily B Member 1), ABL1 (ABL proto-oncogene 1), ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2), AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    See More ...
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    11/24/20
    ST
    -
    CE
    05/01/23
    ST
    -
    FDA
    CRC
    MSI